Literature DB >> 19733383

Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins.

Agnieszka K Witkiewicz1, Thomas McConnell, Magdalena Potoczek, Robert V B Emmons, Robert J Kurman.   

Abstract

Progestins are used to treat complex atypical hyperplasia and well-differentiated endometrial carcinoma in women who desire fertility preservation and those who are poor surgical candidates. Although sensitivity to progestins is thought to be associated with the presence of estrogen and progesterone receptors, it is known that receptor-negative tumors can also respond to the agent, suggesting that there is another direct antitumor action of progestin. Because tumor immune response is an additional predictor of survival in well-differentiated endometrial carcinoma, it is surprising that the role of progestins in tumor immunity has not been investigated. Regulatory T cells modulate the immune response, whereas cytotoxic T cells directly target tumor cells. In this study, we investigated the effect of progestins on regulatory T cells and cytotoxic T cells. The pre- and posttreatment endometrial samples of 15 progestin-treated patients with complex atypical hyperplasia or well-differentiated endometrial carcinoma were evaluated for therapeutic response and the presence of cytotoxic T cells and regulatory T cells. Immunohistochemical analysis was performed for FOXP3 to identify regulatory T cells and for granzyme B to identify activated cytotoxic T cells. To further characterize the cytotoxic T cell's subpopulations, we performed CD8 (cytotoxic T-cell marker) and CD56 (natural killer cells marker). Ten of 15 patients had normal morphology on follow-up endometrial samplings, and 4 patients had persistence or progression of the disease. Regulatory T-cell counts pretreatment were significantly higher in complex atypical hyperplasia and well-differentiated endometrial carcinoma than in posttreatment normal endometrium. Residual complex atypical hyperplasia and well-differentiated endometrial carcinoma present in posttreatment samples maintained high regulatory T cells and low number of cytotoxic T cells. Progestin treatment was associated with striking increase in cytotoxic T cells in areas with decidual reaction. Before treatment, most of the granzyme B+ cytotoxic T cells in complex atypical hyperplasia and well-differentiated endometrial carcinoma were CD8(+) T cells, whereas after treatment, up to 80% of cytotoxic T cells were natural killer cells. These results suggest that progestin treatment affects subpopulations of lymphocytes in the endometrium and may induce immune suppression of complex atypical hyperplasia and well-differentiated endometrial carcinoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19733383     DOI: 10.1016/j.humpath.2009.06.012

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  9 in total

Review 1.  Progesterone: the ultimate endometrial tumor suppressor.

Authors:  Shujie Yang; Kristina W Thiel; Kimberly K Leslie
Journal:  Trends Endocrinol Metab       Date:  2011-02-25       Impact factor: 12.015

2.  Excess Heme Promotes the Migration and Infiltration of Macrophages in Endometrial Hyperplasia Complicated with Abnormal Uterine Bleeding.

Authors:  Lu-Yu Ruan; Zhen-Zhen Lai; Jia-Wei Shi; Hui-Li Yang; Jiang-Feng Ye; Feng Xie; Xue-Min Qiu; Xiao-Yong Zhu; Ming-Qing Li
Journal:  Biomolecules       Date:  2022-06-19

Review 3.  Immunotherapy in endometrial cancer: rationale, practice and perspectives.

Authors:  Wenyu Cao; Xinyue Ma; Jean Victoria Fischer; Chenggong Sun; Beihua Kong; Qing Zhang
Journal:  Biomark Res       Date:  2021-06-16

4.  Endometrial adenocarcinoma in spontaneous abortion: two cases and review of the literature.

Authors:  Feng Zhou; Zhida Qian; Yinghua Li; Jiale Qin; Lili Huang
Journal:  Int J Clin Exp Med       Date:  2015-05-15

5.  Haloperidol and Other Antipsychotics Exposure before Endometrial Cancer Diagnosis: A Population-based Case-control Study.

Authors:  Wei-Ling Chen; Srinivasan Nithiyanantham; Yan-Chiao Mao; Chih-Hsin Muo; Chih-Pin Chuu; Shih-Ping Liu; Min-Wei Huang; Kuan-Pin Su
Journal:  Clin Psychopharmacol Neurosci       Date:  2022-08-31       Impact factor: 3.731

Review 6.  "Iron triangle" of regulating the uterine microecology: Endometrial microbiota, immunity and endometrium.

Authors:  Na Zhu; Xuyan Yang; Qiao Liu; Yahui Chen; Xiaolan Wang; Huanhuan Li; Hong Gao
Journal:  Front Immunol       Date:  2022-08-09       Impact factor: 8.786

7.  Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial.

Authors:  A Orbo; Ab Vereide; M Arnes; I Pettersen; B Straume
Journal:  BJOG       Date:  2013-11-28       Impact factor: 6.531

Review 8.  Endometrial Cancer Immune Escape Mechanisms: Let Us Learn From the Fetal-Maternal Interface.

Authors:  Valentina Bruno; Giacomo Corrado; Denisa Baci; Benito Chiofalo; Maria Antonia Carosi; Livia Ronchetti; Emilio Piccione; Adriana Albini; Douglas M Noonan; Giulia Piaggio; Enrico Vizza
Journal:  Front Oncol       Date:  2020-03-12       Impact factor: 6.244

9.  Immune-related gene ANGPT1 is an adverse biomarker for endometrial carcinoma.

Authors:  Binbin Nong; Tongye Su; Mingyang Jin; Jintai Huang; Aimin Huang; Dalang Fang; Jie Wei
Journal:  Transl Cancer Res       Date:  2021-06       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.